Non-Alcoholic Fatty Liver Disease (NAFLD): The Search for a Cure

Abdulla, Alabagi; Reynolds, Charity A.; A-Kader, H. Hesham

doi:10.33590/emj/10314771

Cited by 3 publications

(1 citation statement)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At present, the US Food and Drug Administration (FDA) does not recognize any drugs specific for NAFLD treatment [24]. However, ongoing research on therapies for obesity-associated NAFLD includes diet and lifestyle modification for weight loss, the use of the supplements and insulin sensitizers, and surgery [25]. Certain risk factor reduction strategies have been reported in the literature: smoking cessation [26], alternate day fasting [27], consumption of probiotics [28], and supplementation with omega-3 fatty acids (n-3s) [29].…”

Section: Introductionmentioning

confidence: 99%

Effects of Fish Oil Supplementation on Reducing the Effects of Paternal Obesity and Preventing Fatty Liver in Offspring

Shrestha,

Dellett,

Yang

et al. 2023

Nutrients

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is a serious public health concern, which calls for appropriate diet/nutrition intervention. Fish oil (FO) has several benefits in reducing obesity, but its intergenerational role in reducing the effects of paternal obesity has not been established. Hence, we hypothesized that FO supplementation to an obese father during the pre-conceptional period could improve the metabolic health of the offspring, specifically in the liver. Three groups of male mice were fed with a low-fat (LF), high-fat (HF), or high-fat diet supplemented with FO (HF-FO) for 10 weeks and were then allowed to mate with female mice fed a chow diet. Offspring were sacrificed at 16 weeks. The liver tissue was harvested for genomic and histological analyses. The offspring of HF and HF-FO fathers were heavier compared to that of the LF mice during 9–16 weeks. The glucose tolerance of the offspring of HF-FO fathers were significantly improved as compared to the offspring of HF fathers. Paternal FO supplementation significantly lowered inflammation and fatty acid synthesis biomarkers and increased fatty acid oxidation biomarkers in the offspring liver. In summary, FO supplementation in fathers shows the potential to reduce metabolic and cardiovascular diseases through genetic means in offspring.

show abstract

Section: Introductionmentioning

confidence: 99%

Effects of Fish Oil Supplementation on Reducing the Effects of Paternal Obesity and Preventing Fatty Liver in Offspring

Shrestha,

Dellett,

Yang

et al. 2023

Nutrients

View full text Add to dashboard Cite

show abstract

Blueberry, combined with probiotics, alleviates non-alcoholic fatty liver diseaseviaIL-22-mediated JAK1/STAT3/BAX signaling

et al. 2018

View full text Add to dashboard Cite

show abstract

Efficacy of Atorvastatin Plus Aspirin in Comparison with Atorvastatin Alone on Liver Function and Degree of Fibrosis in Patients with Cryptogenic Cirrhosis: A Randomized Double-Blind Clinical Trial

et al. 2019

View full text Add to dashboard Cite

Objectives: This study was conducted to evaluate the efficacy of a combination therapy using aspirin (also known as acetylsalicylic acid (ASA)) and atorvastatin in comparison with atorvastatin alone to improve liver fibrosis and function in patients with cryptogenic cirrhosis. Methods:In this randomized double-blinded clinical trail, 40 patients with cryptogenic cirrhosis were randomly allocated to the intervention group (atorvastatin + ASA) and the control group (atorvastatin) treated for six months. Then liver function and stiffness (based on transient electrography) were compared. A checklist was used for data collection and the results were analyzed by SPSS 24 using chi-square test and paired t-test at the 0.05 significance level. Results:A total of 33 cases, including16 patients in group A (atorvastatin + ASA) and 17 in group B (atorvastatin + placebo) with a mean age of 50.3 ± 11.2 and 47.9 ± 10.6 years and BMI of 30.7 ± 4.2 and 30.8± 3.1 in groups A and B, were studied, respectively.Twelve patients (75%) in group A and 14 cases (82%) in group B were male. Both groups were homogenized in terms of demographic information at baseline. A significant improvement in Child score (P = 0.001 and P = 0.002 for groups A and B, respectively) and liver stiffness (P < 0.0001 and P = 0.007 for groups A and B, respectively) were observed in both groups after the intervention, however there was no significant improvement in child score (P = 0.982) and liver stiffness (P = 0.611) in comparing both groups. Conclusions:Although atorvastatin is effective in improvement of liver fibrosis and function in cryptogenic cirrhosis, adding ASA cannot improve its effects.

show abstract

Non-Alcoholic Fatty Liver Disease (NAFLD): The Search for a Cure

Cited by 3 publications

References 76 publications

Effects of Fish Oil Supplementation on Reducing the Effects of Paternal Obesity and Preventing Fatty Liver in Offspring

Effects of Fish Oil Supplementation on Reducing the Effects of Paternal Obesity and Preventing Fatty Liver in Offspring

Blueberry, combined with probiotics, alleviates non-alcoholic fatty liver diseaseviaIL-22-mediated JAK1/STAT3/BAX signaling

Efficacy of Atorvastatin Plus Aspirin in Comparison with Atorvastatin Alone on Liver Function and Degree of Fibrosis in Patients with Cryptogenic Cirrhosis: A Randomized Double-Blind Clinical Trial

Contact Info

Product

Resources

About